Drug Trial Radar · NCT04597125
RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)
Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
654
Actual
Start
Nov 9, 2020
Primary completion
Nov 21, 2025
Study completion Nov 19, 2026
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- Oct 22, 2020
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers in this study want to compare how well drug radium-223 dichloride (Xofigo) and androgen receptor pathway inhibitor (ARPI) therapy work in participants with prostate gland cancer which has spread to the bone and progressed on or after one line of ARPI therapy. Meanwhile researchers want to compare the safety of radium-223 dichloride and ARPI therapy. Radium-223 dichloride is known as a radioactive drug that is taken up by bones after it is injected into the body. It works by giving off a type of radioactivity that travels a very short distance and kills the tumor cells that have spread to the bone without major effects to the healthy cells. It has been approved in many countries for the treatment of patients with prostate cancer which has spread to the bone. The ARPI drugs used in this study will be either abiraterone acetate (Zytiga) (plus prednisone/prednisolone) or enzalutamide (Xtandi). Both of them are standard approved medications which are used in the treatment of advanced prostate cancer. Participants in this study will receive either Radium-223 dichloride or a ARPI therapy. Radium-223 dichloride will be given as an infusion into one of the veins on Day 1 of each 4-week cycle for a total of up to 6 cycles. Oral ARPI therapy will be given per the standard approved dose once daily until the disease has progressed. Participants will visit the hospital or clinic every 2 weeks for the first 6 cycles, and only on the first day of each cycle from cycle 7 and onwards. Observation for each participant will last for about 2 years in total. Blood and urine samples will be collected from the participants and participants will be asked to complete questionnaires about the well-being and the pain.
Conditions
- Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Interventions
Radium-223 dichloride (Xofigo, BAY88-8223)Drug
Participants will receive Radium-223 (BAY88-8223) every 4 weeks for a total of 6 administrations via intravenous (IV) injection
ARPI therapyDrug
Participants will receive continuous ARPI (either Abiraterone acetate plus prednisone/prednisolone \[AAP\] or enzalutamide) by mouth (per os) daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall survival (OS)Time frame: Up to five years
Locations
117 sites in 19 countries. Site status is shown where the registry gives one.
Specialist Services Medical Group
Castle Hill, New South Wales, Australia
Gosford Hospital
Gosford, New South Wales, Australia
Nepean Hospital
Kingswood, New South Wales, Australia
North West Cancer Centre
North Tamworth, New South Wales, Australia
Northern Cancer Institute
St Leonards, New South Wales, Australia
Prince of Wales Hospital NSW
Sydney, New South Wales, Australia
Illawarra Shoalhaven Local Health District
Wollongong, New South Wales, Australia
Icon Cancer Care
Brisbane, Queensland, Australia
Tasman Health Care
Southport, Queensland, Australia
The Tweed Hospital
Tugun, Queensland, Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia
Klinik Ottakring, Wilhelminenspital
Vienna, Lower Austria, Austria
Kepler Universitätsklinikum GmbH
Linz, Upper Austria, Austria
Krajská nemocnice Liberec, a. s.
Liberec, Liberec Region, Czechia
Urocentrum Praha, s.r.o.
Prague, Prague, Czechia
Všeobecná fakultní nemocnice v Praze
Prague, Prague, Czechia
Fakultni Thomayerova Nemocnice
Prague, Prague, Czechia
Fakultní nemocnice Bulovka
Prague, Prague, Czechia
Fakultní nemocnice u sv. Anny v Brně
Brno, South Moravian, Czechia
Krajska Zdravotní, a.s. - Nemocnice Chomutov, o.z. - Onkologické oddělení
Chomutov, Ústí nad Labem Region, Czechia
Oulu University Hospital, Oulun yliopistollinen sairaala (OYS)
Oulu, North Ostrobothnia, Finland
Tampere University Hospital, Tampereen yliopistollinen sairaala (TAYS)
Tampere, Pirkanmaa, Finland
Seinäjoen keskussairaala
Seinäjoki, South Ostrobothnia, Finland
OBSOLETE_Docrates Klinikka
Helsinki, Uusimaa, Finland
Centre Hospitalier Universitaire - Grenoble
La Tronche (Grenoble Area), Auvergne-Rhône-Alpes, France
Unicancer Dijon - Centre Georges Francois Leclerc
Dijon, Bourgogne-Franche-Comté, France
Hôpital Morvan - Brest
Brest, Brittany Region, France
Centre Eugène Marquis - Rennes Cedex
Rennes, Brittany Region, France
Institut de Cancerologie Jean Godinot
Reims, Grand Est, France
CHU Strasbourg - Hopital Hautepierre
Strasbourg, Grand Est, France
Institut de Cancérologie de Lorraine - Alexis Vautrin
Vandœuvre-lès-Nancy, Grand Est, France
Hôpital Henri Mondor
Créteil, Île-de-France Region, France
Gustave Roussy - Departement Oncologie-Radiotherapie
Villejuif, Île-de-France Region, France
CHU de Bordeaux - Hopital Saint Andre
Bordeaux, New Aquitaine, France
Centre de Lutte Contre le Cancer François Baclesse
Caen, Normandy, France
Unicancer Marseille - Institut Paoli-Calmettes
Marseille, Provence-Alpes-Côte d'Azur Region, France
Centre Antoine Lacassagne Nice
Nice, Provence-Alpes-Côte d'Azur Region, France
Universitätsklinikum Münster
Münster, North Rhine-Westphalia, Germany
Universitätsmedizin der Johannes Gutenberg, Universität Mainz
Mainz, Rhineland-Palatinate, Germany
Pamela Youde Nethersole Eastern Hospital
Chai Wan, Hong Kong Island, Hong Kong
Showing 40 of 117 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.